|
SAYING
that a piece of legislation could not, on its own, lower
the prices of medicine, a militant legislator on
Wednesday proposed a five-point legislative agenda that
included the breaking up of the monopoly of large
pharmaceutical companies by amending the Intellectual
Property Code.
Party-list Rep. Risa Hontiveros blamed the monopoly of
large pharmaceutical companies as the culprit behind the
exorbitant prices of medicines in the country.
“We
should break this monopoly. Anything less would not
lower the cost of essential drugs in the country,” said
Hontiveros.
During a
roundtable discussion between legislators and experts
from the World Health Organization, Hontiveros expressed
optimism that a bipartisan consensus would be achieved
to pass measures on cheaper medicines.
“We
should not allow partisan politics, especially the 2010
presidential elections, to hostage the enactment of
bills on cheaper medicines,” Hontiveros said.
She
warned that if it is true that pharmaceutical companies
have a P1-billion lobby kit, then they would capitalize
on disagreements between what version should be
prioritized.
Hontiveros said a package of legislation is needed to
bring down the price of medicines.
Besides
the breaking up of the monopoly of large pharmaceutical
companies, part of the package of legislation Hontiveros
is proposing are the introduction of price control and
transparency mechanisms, which should be outside the
influence of pharmaceutical companies; introduction of
fair-pricing mechanisms for Philhealth; and increase the
bargaining power of the government with insurance for
out-of-pocket expenses; review and strengthening of the
Generics Act and establishment of a domestic
pharmaceutical industry capable of producing active
ingredients, which requires the strengthening of the
Bureau of Food and Drugs; increased support for herbal
medicines; and a fine chemical industry.
“What we
have so far are measures to amend the IPC, introduce
fair pricing for Philhealth and price-control
mechanisms. Admittedly, these measures would not
immediately usher a drastic reduction in the price of
medicines, but they would still improve access to
essential medicines. The challenge now is to have the
political will to broaden the legislative agenda for
cheaper medicines and prioritize these measures,”
Hontiveros said. |